相关文献 [1]. Yanagisawa M, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988 Aug 25;332(6163):411 - 5. [2]. Masaki T. Endothelin: discovery and ...

a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide ...

Commercial success of VINIA validates the power of BioHarvest's patented Botanical Synthesis technology to produce valuable plant-based Compounds ...

Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGSNet product sales of FILSPARI ...

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) gapped down prior to trading on Friday after the company announced weaker than expected quarterly earnings. The stock had ...

After hours: February 20 at 4:20:00 PM EST Loading Chart for LGND ...

Following an admission to the authors’ centre with severe anaemia, duodenal biopsy confirmed the diagnosis of Whipple’s ...

Department of Pharmacology and Toxicology, National Institutes of Pharmaceutical Education and Research (NIPER), organised a workshop on “Drug discovery and development in mew Millennium- 4” (D3NM-4) ...

The PAH treatment market is expected to grow from USD 5,811.5 million in 2023 to USD 7,224.4 million by 2033, at a CAGR of ...

Louisiana State Employees Retirement System boosted its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 3.4% during the 4th quarter, according to the company ...